Last Update: Mar 15, 2024
A Post Approval Surveillance of Scemblix® (Asciminib) in Patients With Chronic Myeloid Leukemia (CML) in Korea
ClinicalTrials.gov Identifier:
NCT05943522
Novartis Reference Number:CABL001A2006
See if you Pre-qualify
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study is a prospective, open-label, multi-center, non-comparative, observational
study to assess safety and effectiveness of Asciminib in the real-world clinical setting
in Korean Chronic myeloid leukemia (CML) patients. The dosage and duration of treatment may be considered and decided by the investigator in
accordance with prescribing information of Asciminib.

This study will enroll all patients by total enumeration for those prescribed with
Asciminib at physicians' discretion as per locally approved label under usual clinical
practice for 2 years after the market launch.

Chronic Myeloid Leukemia
Recruiting
100
Jul 19, 2023
Jul 31, 2025
All
18 Years - (Adult, Older Adult)

Interventions

Other

Asciminib

There is no treatment allocation. Asciminib will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis

Eligibility Criteria

Inclusion criteria

1. Adult patients diagnosed with Ph+ CP-CML and currently receiving or going to receive
Scemblix® treatment according to locally approval label

2. Patients who are willing to provide written informed consent prior to study
enrollment

Exclusion criteria

1. Patients with contraindication according to locally approved label of Scemblix®

2. Patients who receive or are going to receive any investigational medicine during the
observation period

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

+41613241111